Resonant Sciences Acquisition Adds Defense Angle but Doesn't Fix Core Delays

What happened

Joby Aviation shares have fallen more than 50% over the past twelve months, and the stock now trades around $8.42. A Motley Fool article today frames the acquisition of defense-technology company Resonant Sciences for $500 million as a simple reason to buy the stock. The deal adds a defense electronics capability but consumes almost a quarter of Joby's $2.264 billion liquidity, while the company still burns over $400 million in free cash flow annually. The DeepValue report's WAIT rating is premised on near-term FAA certification milestones, Toyota's second $250 million tranche, and Dubai launch timing, none of which this acquisition directly addresses. Therefore, the acquisition is unlikely to change the investment thesis on its own and may introduce integration risk and capital allocation questions.

Implication

The $500 million outlay reduces Joby's financial flexibility, even though the company retains over $1.7 billion in liquidity after the deal. Defense revenue is not yet a proven driver of valuation for Joby, and the acquisition's contribution to near-term cash flow is uncertain. The core thesis still depends on FAA for-credit TIA testing, closure of Toyota's second tranche, and a firm Dubai launch date, and this deal does nothing to accelerate those. If the acquisition is financed with equity or additional debt, it could dilute holders or increase leverage at a time when the balance sheet is already carrying $701.9 million in long-term debt. Maintain exposure at or below the current WAIT position, and only reconsider if the defense segment shows concrete contracted revenue or the original milestones begin to land.

Thesis delta

The prior thesis was that Joby is a WAIT until at least one hard catalyst (FAA TIA, Toyota tranche, Dubai launch) materializes. The Resonant Sciences acquisition does not shift that thesis; it adds a new defense vertical but consumes meaningful cash without addressing certification or manufacturing bottlenecks. If anything, it increases execution complexity and reduces the margin for delay, but it does not change the WAIT rating or valuation scenarios.